ReviewJournal of cardiovascular development and disease2023
Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration-A Novel Mechanism of Action.
Review in Journal of cardiovascular development and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Exploration and clinical analysis of the correlation between the triglyceride-glucose index and hyperuricemia in patients with type 2 diabetes: a real-world, retrospective, cross-sectional study with subsequent cohort analysis.BMC endocrine disorders · 2026Article
- Efficacy of dapagliflozin on uric acid in patients with moderate-to-severe chronic kidney disease.Clinical and experimental nephrology · 2026Article
- Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors for Uricosuria.Electrolyte & blood pressure : E & BP · 2025Review
- Effect of Glomerular Filtration Rate on Uric Acid Metabolism in a Retrospective Cohort of Type-2 Diabetes Mellitus Patients on SGLT-2 Inhibitor Therapy.Journal of clinical practice and research · 2025Article
- Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis.Frontiers in pharmacology · 2025Article
- New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.Diagnostics (Basel, Switzerland) · 2024Article
- Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers.Kidney international reports · 2024Review
- Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update.Cardiology journal · 2024Article
- Hyperuricemia as a Risk Factor in Hypertension among Patients with Very High Cardiovascular Risk.Healthcare (Basel, Switzerland) · 2023Article
- The Dual Role of Uric Acid: Pathological Implications Across Chronic Diseases and Current Approaches to Hyperuricemia Management.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are glucose-lowering agents whose positive impact on cardiovascular risk has been described extensively. Not only do they influence lipid profile, blood pressure, atherosclerosis risk, hemoglobin level, and insulin resistance, but they also reduce cardiovascular events, all-cause mortality, and hospitalization rates. Some of these effects may be due to their impact on serum uric acid (SUA) concentration. Findings from nine meta-analyses showed that, indeed, SGLT2is significantly reduce SUA. The data on the drug- and dose-dependency of this effect were inconclusive. Several factors alternating the beneficial effects of SGLT2is on SUA, such as glycated hemoglobin concentration (HbA1c), presence of diabetes, and baseline SUA level, were described. Even though there is a consensus that the lowering of SUA by SGLT2is might be due to the increased urinary excretion rate of uric acid (UEUA) rather than its altered metabolism, the exact mechanism remains unknown. The influence of SGLT2is on SUA may not only be used in gout treatment but may also be of huge importance in explaining the observed pleiotropic effects of SGLT2is.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.